Southwest Airlines (LUV) - FREE Research Report

Montford John T who is Director at Southwest Airlines sold 2,000 shares at $18.96 on Dec. 2, 2013. Following this transaction, the Director owned 25,143 shares meaning that the stake was reduced by 7.37% with the 2,000-share transaction.

The shares most recently traded at $18.22, down $0.74, or 4.09% since the insider transaction. Historical insider transactions for Southwest Airlines go as follows:

  • 4-Week # shares sold: 124,551
  • 12-Week # shares sold: 139,163
  • 24-Week # shares sold: 139,163

The average volume for Southwest Airlines has been 6.8 million shares per day over the past 30 days. Southwest Airlines has a market cap of $13.0 billion and is part of the services sector and transportation industry. Shares are up 81.54% year-to-date as of the close of trading on Monday.

Southwest Airlines Co. operates passenger airlines that provide scheduled air transportation services in the United States. As of December 31, 2012, the company operated 694 aircraft, including 606 Boeing 737 aircraft and 88 Boeing 717 aircraft. The stock currently has a dividend yield of 0.86%. The company has a P/E ratio of 21.6. Currently there are 7 analysts that rate Southwest Airlines a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LUV - FREE

TheStreet Quant Ratings rates Southwest Airlines as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Southwest Airlines Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Stock Observations; Reviewing Equities: Doug Kass' Views

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Teva's New CEO Brings This Secret Weapon

Will Allergan's Deal With Tribe Hold Up?

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)